These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31762422)

  • 1. Drug Discovery by Targeting Mutant KRAS.
    Ye N
    Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting Mutant KRAS for Anticancer Therapy.
    Chen F; Alphonse MP; Liu Y; Liu Q
    Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma.
    Nastasă C; Tamaian R; Oniga O; Tiperciuc B
    Medicina (Kaunas); 2019 Mar; 55(4):. PubMed ID: 30935124
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.
    Perurena N; Cichowski K
    Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undruggable KRAS-time to rebrand?
    The Lancet Oncology
    Lancet Oncol; 2021 Mar; 22(3):289. PubMed ID: 33662279
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting the KRAS G12C mutation in patients with advanced solid tumors.
    Hong DS
    Clin Adv Hematol Oncol; 2019 Nov; 17(11):612-614. PubMed ID: 31851163
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct KRAS inhibition: progress, challenges, and a glimpse into the future.
    Grapsa D; Syrigos K
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):437-440. PubMed ID: 32320301
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting RAS: The Elusive Prize.
    Bates SE
    Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
    Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
    J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in targeting RAS with small molecule drugs.
    McCormick F
    Biochem J; 2019 Jan; 476(2):365-374. PubMed ID: 30705085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
    Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
    Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378
    [No Abstract]   [Full Text] [Related]  

  • 14. Discoveries in the redox regulation of KRAS.
    Kramer-Drauberg M; Ambrogio C
    Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers.
    He H; Xu C; Cheng Z; Qian X; Zheng L
    Curr Top Med Chem; 2019; 19(23):2128-2142. PubMed ID: 31475900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS
    Cagir A; Azmi AS
    Future Med Chem; 2019 May; 11(9):923-925. PubMed ID: 31140867
    [No Abstract]   [Full Text] [Related]  

  • 19. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Research Progress of Direct KRAS G12C Mutation Inhibitors.
    Yang A; Li M; Fang M
    Pathol Oncol Res; 2021; 27():631095. PubMed ID: 34257597
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.